Amylyx Pharmaceuticals (AMLX) Return on Capital Employed (2022 - 2026)

Amylyx Pharmaceuticals' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 12.24% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 2330.0% year-over-year to 12.24%; the TTM figure through Mar 2026 stood at 12.24% (down 2330.0% YoY), while the FY2025 annual figure was 12.64%, up 676.0% from the prior year.
• Return on Capital Employed was 12.24% for Q1 2026 at Amylyx Pharmaceuticals, down from 9.35% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 37.15% in Q3 2025 to a low of 114.58% in Q3 2024.
• Historically, Return on Capital Employed has averaged 33.19% across 5 years, with a median of 22.12% in 2023.
• The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 11271 bps in 2024, then soared 15172 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 83.95% in 2022, then soared by 111 bps to 9.46% in 2023, then tumbled by 446 bps to 32.74% in 2024, then soared by 71 bps to 9.35% in 2025, then sank by 31 bps to 12.24% in 2026.
• The last three Return on Capital Employed figures came in at 12.24% (Q1 2026), 9.35% (Q4 2025), and 37.15% (Q3 2025), per Business Quant data.